Hat mitgewirkt an:
-
Costs of Illness of Spinal Muscular Atrophy: A Systematic Review
-
Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment
-
Costs of illness of spinal muscular atrophy: a systematic review
-
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study